These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2421273)

  • 21. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias.
    Atkinson AJ; Lertora JJ; Kushner W; Chao GC; Nevin MJ
    Clin Pharmacol Ther; 1983 May; 33(5):565-76. PubMed ID: 6188570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation.
    Piergies AA; Ruo TI; Jansyn EM; Belknap SM; Atkinson AJ
    Clin Pharmacol Ther; 1987 Jul; 42(1):107-12. PubMed ID: 2439251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A new anti-arrhythmia drug. II. Comparative studies of the effects of a new acyl derivative of procainamide, procainamide and N-acetylprocainamide on blood pressure and the electrocardiogram in rabbits].
    Kusowska J
    Acta Pol Pharm; 1989; 46(1):90-7. PubMed ID: 2479226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-related pharmacokinetics of N-acetylprocainamide in rats.
    Yacobi A; Kamath BL; Stampfli HF; Look ZM; Lai CM
    J Pharm Sci; 1983 Jul; 72(7):789-92. PubMed ID: 6193264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of procainamide hydrochloride in dogs.
    Papich MG; Davis LE; Davis CA; McKiernan BC; Brown SA
    Am J Vet Res; 1986 Nov; 47(11):2351-8. PubMed ID: 2431636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of the acetylation phenotype and the therapeutic effect of procainamide.
    Schröder P; Klitgaard NA; Simonsen E
    Eur J Clin Pharmacol; 1979 Feb; 15(1):63-8. PubMed ID: 84761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue distribution of N-acetylprocainamide in rats.
    Yacobi A; Stampfli HF; Lai CM; Kamath BL
    Drug Metab Dispos; 1981; 9(3):193-5. PubMed ID: 6166443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-Acetylprocainamide kinetics and clinical response during repeated dosing.
    Rodman JH; Hurst A; Gaarder T; Cohen J; Jelliffe RW
    Clin Pharmacol Ther; 1982 Sep; 32(3):378-86. PubMed ID: 6179685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of desethyl procainamide in patients: a new metabolite of procainamide.
    Ruo TI; Morita Y; Atkinson AJ; Henthorn T; Thenot JP
    J Pharmacol Exp Ther; 1981 Feb; 216(2):357-62. PubMed ID: 6162026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide.
    Atkinson AJ; Ruo TI; Piergies AA
    Angiology; 1988 Jul; 39(7 Pt 2):655-67. PubMed ID: 2457345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aging and renal clearance of procainamide and acetylprocainamide.
    Reidenberg MM; Camacho M; Kluger J; Drayer DE
    Clin Pharmacol Ther; 1980 Dec; 28(6):732-5. PubMed ID: 6160015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lethal accumulation of procainamide metabolite in severe renal insufficiency.
    Vlasses PH; Ferguson RK; Rocci ML; Raja RM; Porter RS; Greenspan AM
    Am J Nephrol; 1986; 6(2):112-6. PubMed ID: 2422935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutics effects and serum concentration of low doses of procainamide (author's transl)].
    Mazurowa A; Skretkowicz J; Wisławska-Orłowska B; Alwasiak B; Dobrska-Drobnik G
    Przegl Lek; 1980; 37(4):417-9. PubMed ID: 6157177
    [No Abstract]   [Full Text] [Related]  

  • 34. [Comparative effectiveness of neogilurytmal, novocainamide, ethmozin, disopyramide and ethacizin in supraventricular extrasystole].
    Shpektor AV; Gorshkov VA; Mamaev VI; Sherashov VS; Kurakina TI
    Sov Med; 1986; (12):96-7. PubMed ID: 2436318
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term antiarrhythmic therapy with acetylprocainamide.
    Kluger J; Leech S; Reidenberg MM; Lloyd V; Drayer DE
    Am J Cardiol; 1981 Dec; 48(6):1124-32. PubMed ID: 6171156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations.
    Bauer LA; Black D; Gensler A; Sprinkle J
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):213-6. PubMed ID: 2472362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acecainide for ventricular arrhythmias.
    Vyden JK
    JAMA; 1982 Feb; 247(5):581. PubMed ID: 6172606
    [No Abstract]   [Full Text] [Related]  

  • 38. [Comparative evaluation of the anti-arrhythmic activity of carbamazepine, novocainamide and obzidan in ventricular extrasystole].
    Logosha IuI; Kamalova EG; Khusainova FS
    Farmakol Toksikol; 1986; 49(6):71-3. PubMed ID: 2434357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis.
    Stec GP; Atkinson AJ; Nevin MJ; Thenot JP; Ruo TI; Gibson TP; Ivanovich P; del Greco F
    Clin Pharmacol Ther; 1979 Nov; 26(5):618-28. PubMed ID: 91468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of N-acetylprocainamide deacetylation.
    Stec GP; Ruo TI; Thenot JP; Atkinson AJ; Morita Y; Lertora JJ
    Clin Pharmacol Ther; 1980 Nov; 28(5):659-66. PubMed ID: 6160014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.